From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
about
Selective gene silencing by viral delivery of short hairpin RNATherapeutic application of RNAi: is mRNA targeting finally ready for prime time?Adeno-associated virus: from defective virus to effective vectorStructural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6Gene delivery to the spinal cord using MRI-guided focused ultrasoundImaging the response of the retina to electrical stimulation with genetically encoded calcium indicators.Adeno-associated viral vectors engineered for macrolide-adjustable transgene expression in mammalian cells and miceIn vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties.Characterization of genome integrity for oversized recombinant AAV vector.AAV's anatomy: roadmap for optimizing vectors for translational successpH-responsive polymeric micelle carriers for siRNA drugs.Genetic vaccines for anthrax based on recombinant adeno-associated virus vectorsEfficient intrathymic gene transfer following in situ administration of a rAAV serotype 8 vector in mice and nonhuman primates.A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia.pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1.Primate models of schizophrenia: future possibilities.Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization propertiesLiver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Characterization of the capsid protein glycosylation of adeno-associated virus type 2 by high-resolution mass spectrometry.Syntaxin 5-dependent retrograde transport to the trans-Golgi network is required for adeno-associated virus transduction.Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune responseAdvances in AAV-mediated gene transfer for the treatment of inherited disorders.Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway.Intracellular transport of recombinant adeno-associated virus vectors.Gene therapy of liver diseases.Recombinant adeno-associated virus vectors for gene therapy.Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advancesAlleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules.Intracellular trafficking of adeno-associated viral vectors.
P2860
Q21245112-8E245085-7122-4C75-A9F1-19625F95C014Q24669624-DFF8AA7C-60D3-4C55-9604-69AFBCDE7210Q27498163-CECA6EC1-4AEB-44B6-9EF9-B7D132850572Q27664641-00A5D163-7852-4B81-9CDA-709989D4BB35Q30394722-A56E0913-1B23-4DB9-AEDD-9B4913A4D2ADQ30538922-0F6C1CA6-97F3-40A5-9386-0D8CD1CF9926Q33305143-AB0C460A-122C-4CA9-B24E-403CBA2F733DQ33327474-6A3198F9-EE35-4C7D-A6D3-3DF3750C083CQ33555259-4D1B0FF0-B57B-419E-BAAB-386563B1BD12Q33576852-173EE9AC-DB21-4C77-A8E3-D550CEB19568Q33659389-AD188897-E479-47E1-AED0-14927BC9F2BCQ33708003-A80030FB-7A97-49FC-8C2B-23D2C173D51FQ33713243-1CD5B9B4-0DA1-42D5-99F6-EA2A7ABFF14AQ33713355-05494E9B-42A7-4322-90B0-5735DEC6C986Q33864423-65027915-058C-48FD-B4F4-ADC0D2279249Q34059878-5D8B53FB-D2FB-4B6A-8999-1B3C4A043BF2Q34090316-BA3BBF73-649A-4690-9D80-50E7DE1D155BQ34227421-5103D1F9-34A7-4592-8E06-38E17D5A7951Q34228552-54AEF36D-0936-45F9-ACE4-D92243251743Q34233154-0F2AA15B-68C2-4E01-BCA3-76A835C255BCQ34434903-12B35E81-C6D4-41B7-9D76-BBE028ADE38CQ34530552-66ECD659-6EC9-4FF4-A192-28E1CE1F461CQ34566454-4EC5C8D7-93A3-4303-8B2C-6705519A0176Q34651465-3E587D5B-5700-48B8-BF32-DE0C79BCA1DCQ34991404-1D39B57A-0B2A-4CD6-9619-EA6E3782BAD6Q35024289-32F0248A-263C-466B-A80E-6A7DB7DE586AQ35025591-33B5637D-725D-41B4-8318-998A8848977DQ35101411-A844BF1B-6D48-4307-8BEB-9C5D42F065FDQ35239472-4623B616-9C6F-4393-BDA8-F3ABD74CB4BAQ35568518-9F9B866D-10F2-4924-AC43-613102A341FDQ35628533-AA33EC07-4E09-47E0-AF29-3902E8405936Q35669676-E3C7CAAA-0280-4F77-80AE-3FC46E0EEDCCQ35734826-95DC53C0-82E9-43E8-A923-3E0C4E1F22D5Q35842662-C3494318-57AF-4333-8B9D-7F4736668BCCQ35842668-9C100E31-4620-4474-B5B8-0E2149958DA8Q35847178-99AC43A9-5309-4158-A904-CBB5ED83585DQ35910008-9378FB81-7170-479E-A5F0-2CA2DFEF3699Q35960506-DD1B1702-FCBE-4F94-B244-B975C58F5998Q36040794-38B07D5F-DD0F-4958-BD6E-656C073EFF77Q36097743-138472F2-C3AF-4091-9857-DB0DC5D4FA90
P2860
From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
From virus evolution to vector ...... ectors for human gene therapy.
@ast
From virus evolution to vector ...... ectors for human gene therapy.
@en
type
label
From virus evolution to vector ...... ectors for human gene therapy.
@ast
From virus evolution to vector ...... ectors for human gene therapy.
@en
prefLabel
From virus evolution to vector ...... ectors for human gene therapy.
@ast
From virus evolution to vector ...... ectors for human gene therapy.
@en
P356
P1433
P1476
From virus evolution to vector ...... ectors for human gene therapy.
@en
P304
P356
10.2174/1566523034578285
P407
P577
2003-08-01T00:00:00Z